drugset / Trial / NCT04134897
Neoadjuvant Chemotherapy in Patients With Moderate Risk Mid Rectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether 3 months of neoadjuvant CapOx is non-inferior to neoadjuvant radiotherapy in patients with moderate risk CRM"-" mid rectal cancer.
Timeline
- Start
- 2019-10-14
- Primary completion
- 2024-10
- Completion
- 2024-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 825 mg/m2 | Oral |
| Subject | Capecitabine | Small molecule | 2000 mg/m2 | Oral |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |